RT Journal Article
SR Electronic
T1 HIF2α Antagonism Has Antitumor Activity in Advanced ccRCC
JF Cancer Discovery
JO Cancer Discov
FD American Association for Cancer Research
DO 10.1158/2159-8290.CD-RW2018-007
YR 2018
UL http://cancerdiscovery.aacrjournals.org/content/early/2018/01/11/2159-8290.CD-RW2018-007.abstract
AB The HIF2α antagonist PT2385 achieved responses in 14% of patients with heavily pretreated ccRCC.